Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children

Study to Evaluate the Human Infection of the Lower Respiratory Tract in Children at High Risk

NCT00192439 ·Status: COMPLETED

A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults

NCT02298179 ·Status: COMPLETED ·Phase: PHASE1

Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV Infection

NCT00192504 ·Status: COMPLETED ·Phase: PHASE1

RSV Observational Study 2

NCT01922648 ·Status: COMPLETED

Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children

NCT01459198 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness

NCT00421304 ·Status: COMPLETED ·Phase: NA

Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children

NCT02601612 ·Status: COMPLETED ·Phase: PHASE1

A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older

NCT03982199 ·Status: TERMINATED ·Phase: PHASE2

A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age

NCT05900154 ·Status: COMPLETED ·Phase: PHASE1

Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract

NCT02254421 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age

NCT03303625 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

NCT02237209 ·Status: COMPLETED ·Phase: PHASE1

Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.

NCT05035212 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)

NCT06077149 ·Status: COMPLETED ·Phase: PHASE4

RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness

NCT00632463 ·Status: COMPLETED ·Phase: PHASE2

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

NCT01852266 ·Status: COMPLETED ·Phase: PHASE1

Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV)

NCT06067191 ·Status: COMPLETED ·Phase: PHASE1

A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults

NCT03529773 ·Status: COMPLETED ·Phase: PHASE2

Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children

NCT03596801 ·Status: COMPLETED ·Phase: PHASE1

Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age

NCT04520659 ·Status: COMPLETED ·Phase: PHASE1

A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults.

NCT06473519 ·Status: COMPLETED ·Phase: PHASE3

Novel Mucosal Correlates Of RSV Protection In Older Adults

NCT06274619 ·Status: COMPLETED ·Phase: NA

Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in Healthy Adults

NCT05118386 ·Status: COMPLETED ·Phase: PHASE1

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to <24 Month-Old Children

NCT00767416 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Phase I, Randomized, Double-Blind, Single-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-557

NCT00578682 ·Status: COMPLETED ·Phase: PHASE1